tradingkey.logo


tradingkey.logo


Clearpoint Neuro Inc

CLPT
8.894USD
-0.496-5.28%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
8.99MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Clearpoint Neuro Inc āļšāļĢāļīāļĐāļąāļ—

ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.

āļ‚āđ‰āļ­āļĄāļđāļĨ Clearpoint Neuro Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™CLPT
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Clearpoint Neuro Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJul 03, 2019
āļ‹āļĩāļ­āļĩāđ‚āļ­Burnett (Joseph Michael)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™115
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Jul 03
āļ—āļĩāđˆāļ­āļĒāļđāđˆ120 S. Sierra Avenue
āđ€āļĄāļ·āļ­āļ‡SOLANA BEACH
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ92075
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ19499006833
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.clearpointneuro.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™CLPT
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJul 03, 2019
āļ‹āļĩāļ­āļĩāđ‚āļ­Burnett (Joseph Michael)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Clearpoint Neuro Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
380.68K
+27.41%
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
79.75K
+1.11%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
67.34K
+33.96%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+41.75%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-24.94%
Mr. Pascal E.R. Girin
Mr. Pascal E.R. Girin
Independent Director
Independent Director
--
--
Mr. R. John Fletcher
Mr. R. John Fletcher
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. B. Kristine (Kris) Johnson
Ms. B. Kristine (Kris) Johnson
Independent Director
Independent Director
--
--
Mr. Danilo D' Alessandro
Mr. Danilo D' Alessandro
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Linda M. Liau
Dr. Linda M. Liau
Independent Director
Independent Director
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
380.68K
+27.41%
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
79.75K
+1.11%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
67.34K
+33.96%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+41.75%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-24.94%
Mr. Pascal E.R. Girin
Mr. Pascal E.R. Girin
Independent Director
Independent Director
--
--

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Products: Functional neurosurgery
3.42M
38.62%
Services: Biologics and drug delivery
3.11M
35.10%
Products: Biologics and drug delivery
1.29M
14.58%
Product Systems and software products
647.00K
7.30%
Services: Capital equipment and other
390.00K
4.40%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
8.86M
100.00%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Products: Functional neurosurgery
3.42M
38.62%
Services: Biologics and drug delivery
3.11M
35.10%
Products: Biologics and drug delivery
1.29M
14.58%
Product Systems and software products
647.00K
7.30%
Services: Capital equipment and other
390.00K
4.40%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 25 āļĄāļĩ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 25 āļĄāļĩ.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
6.11%
The Vanguard Group, Inc.
5.96%
MAK Capital One, LLC
5.83%
Bigger Capital Funds, LP
4.49%
PTC Therapeutics Inc
3.02%
āļ­āļ·āđˆāļ™ āđ†
74.60%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
6.11%
The Vanguard Group, Inc.
5.96%
MAK Capital One, LLC
5.83%
Bigger Capital Funds, LP
4.49%
PTC Therapeutics Inc
3.02%
āļ­āļ·āđˆāļ™ āđ†
74.60%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
23.88%
Hedge Fund
16.25%
Investment Advisor/Hedge Fund
9.60%
Individual Investor
5.67%
Corporation
3.02%
Research Firm
1.41%
Bank and Trust
0.14%
Venture Capital
0.07%
Pension Fund
0.03%
āļ­āļ·āđˆāļ™ āđ†
39.93%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
238
11.91M
42.82%
-795.00
2025Q3
241
11.91M
44.93%
+805.07K
2025Q2
228
11.11M
37.29%
+1.29M
2025Q1
216
9.82M
36.04%
-268.85K
2024Q4
204
9.20M
33.04%
+1.04M
2024Q3
190
8.15M
32.05%
-235.56K
2024Q2
185
8.39M
33.08%
-454.38K
2024Q1
183
8.85M
30.95%
+359.48K
2023Q4
183
7.82M
35.41%
+717.11K
2023Q3
184
7.11M
35.71%
+336.40K
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
BlackRock Institutional Trust Company, N.A.
1.63M
5.47%
+127.17K
+8.48%
Sep 30, 2025
The Vanguard Group, Inc.
1.50M
5.03%
+22.52K
+1.53%
Sep 30, 2025
Bigger Capital Funds, LP
1.29M
4.34%
+126.00K
+10.80%
Sep 30, 2025
PTC Therapeutics Inc
894.58K
3.01%
--
--
Aug 23, 2024
Geode Capital Management, L.L.C.
656.40K
2.21%
+31.60K
+5.06%
Sep 30, 2025
State Street Investment Management (US)
482.65K
1.62%
+149.27K
+44.77%
Sep 30, 2025
Millennium Management LLC
187.80K
0.63%
+87.93K
+88.04%
Sep 30, 2025
Burnett (Joseph Michael)
276.33K
0.93%
+254.00
+0.09%
Dec 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Invesco NASDAQ Future Gen 200 ETF
1.19%
iShares Neuroscience and Healthcare ETF
0.94%
iShares Micro-Cap ETF
0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
Vanguard US Momentum Factor ETF
0.06%
Motley Fool Next Index ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
iShares Russell 2000 Growth ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Invesco NASDAQ Future Gen 200 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.19%
iShares Neuroscience and Healthcare ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.94%
iShares Micro-Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.09%
Vanguard US Momentum Factor ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.06%
Motley Fool Next Index ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.03%
iShares Russell 2000 Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.03%
iShares Russell 2000 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.02%
Proshares Ultra Russell 2000
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.02%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™